Chelsea Therapeutics International Ltd.
(NASDAQ : CHTP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 1.32%697.332.6%$644.85m
MRNAModerna, Inc. -0.55%123.640.0%$634.51m
AMGNAmgen, Inc. -0.34%226.971.4%$624.69m
GILDGilead Sciences, Inc. -1.43%62.861.0%$494.49m
VRTXVertex Pharmaceuticals, Inc. -1.01%283.451.9%$355.83m
ILMNIllumina, Inc. -1.61%190.383.2%$291.37m
SNSSSunesis Pharmaceuticals, Inc. -5.81%4.050.7%$283.11m
BIIBBiogen, Inc. -1.42%197.781.8%$184.42m
SAVACassava Sciences, Inc. -18.00%41.870.0%$173.71m
BNTXBioNTech SE -1.27%128.350.0%$100.39m
NRBONeuroBo Pharmaceuticals, Inc. -6.44%15.540.0%$89.03m
NVAXNovavax, Inc. -6.42%21.0075.6%$85.66m
BMRNBioMarin Pharmaceutical, Inc. -0.09%84.844.2%$76.07m
EXASEXACT Sciences Corp. -2.74%33.4117.6%$71.49m
CRSPCRISPR Therapeutics AG -2.68%63.160.6%$69.53m

Company Profile

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.